Raw Ground Truth
Inclusion Criteria:Diagnosis of High Grade glioma that has relapsed, progressed or failed to respond to frontline therapyDiagnosis of Low Grade glioma and require treatment but are unable to undergo further surgical resectionConfirmed measurable diseaseExclusion Criteria:Previous treatment with dabrafenib, trametinib, other RAF inhibitor, other MEK or ERK inhibitorCancer treatment within the past 3 weeksStem cell transplant within the past 3 monthsHistory of heart diseasePregnant or lactating females
Raw Prediction
Amended Eligibility Criteria (version 14):
**Inclusion Criteria:**
1. Diagnosis of High Grade Glioma (HGG) or Low Grade Glioma (LGG).
2. Relapsed, progressed, or failed to respond to frontline therapy.
3. Local and centrally confirmed measurable disease for enrollment.
4. Local histological diagnosis of HGG is sufficient for study entry.
5. Positive BRAF V600 mutation status.
6. Able to swallow capsules.
7. Local and centrally confirmed BRAF V600 mutation status.
8. Local and centrally confirmed HGG histopathology for HGG patients.
9. Willingness to follow all contraception guidance.
10. No history of heart disease.
11. No Gilbert’s syndrome (specific laboratory criteria for inclusion).
**Exclusion Criteria:**
1. Previous treatment with dabrafenib, trametinib, other RAF inhibitors, other MEK or ERK inhibitors.
2. Cancer treatment within the past 3 weeks.
3. Stem cell transplant within the past 3 months.
4. History of heart disease.
5. Pregnant or lactating females.
6. Known allergy to dabrafenib, trametinib, or their excipients.
7. Measurable disease in the LGG cohort (optional but a new baseline tumor evaluation must be established within 28 days of starting dabrafenib in combination with trametinib crossover treatment for LGG patients).
8. Patients who have not met the inclusion criteria for cardiac function or who cannot meet the exclusion criteria for allergy to dabrafenib, trametinib, or their excipients.
Processed Ground Truth
1. Diagnosis of High Grade glioma that has relapsed, progressed or failed to respond to frontline therapyDiagnosis of Low Grade glioma and require treatment but are unable to undergo further surgical resectionConfirmed measurable diseaseExclusion Criteria:Previous treatment with dabrafenib, trametinib, other RAF inhibitor, other MEK or ERK inhibitorCancer treatment within the past 3 weeksStem cell transplant within the past 3 monthsHistory of heart diseasePregnant or lactating females
Processed Prediction
1. Amended Eligibility Criteria (version 14):
1. Diagnosis of High Grade Glioma (HGG) or Low Grade Glioma (LGG).
2. Relapsed, progressed, or failed to respond to frontline therapy.
3. Local and centrally confirmed measurable disease for enrollment.
4. Local histological diagnosis of HGG is sufficient for study entry.
5. Positive BRAF V600 mutation status.
6. Able to swallow capsules.
7. Local and centrally confirmed BRAF V600 mutation status.
8. Local and centrally confirmed HGG histopathology for HGG patients.
9. Willingness to follow all contraception guidance.
10. No history of heart disease.
11. No Gilbert’s syndrome (specific laboratory criteria for inclusion).
1. Previous treatment with dabrafenib, trametinib, other RAF inhibitors, other MEK or ERK inhibitors.
2. Cancer treatment within the past 3 weeks.
3. Stem cell transplant within the past 3 months.
4. History of heart disease.
5. Pregnant or lactating females.
6. Known allergy to dabrafenib, trametinib, or their excipients.
7. Measurable disease in the LGG cohort (optional but a new baseline tumor evaluation must be established within 28 days of starting dabrafenib in combination with trametinib crossover treatment for LGG patients).
8. Patients who have not met the inclusion criteria for cardiac function or who cannot meet the exclusion criteria for allergy to dabrafenib, trametinib, or their excipients.